Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Institut de Recherches Internationales Servier
Woman and Man Max 99 years
Institut de Recherches Internationales Servier (France)
Update Il y a 4 ans
Efficacy of agomelatine given orally on rest/activity circadian rhythms in outpatients with major depressive disorder: a randomised, double-blind international study with parallel groups versus Selective Serotonin Reuptake Inhibitor (SSRI). Six-week treatment plus optional continuation for 18 weeks
Not provided at time of registration and not expected to be available in the future
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Institut de Recherches Internationales Servier
Update Il y a 4 ans
Efficacy and safety of 3 doses (0.25, 0.5 and 1mg/day) of agomelatine sublingual administration over an 8-week treatment period, in out-patients with Major Depressive Disorder. An 8-week randomised, double-blind, fixed dose, international multicentre, placebo-controlled study with parallel groups, followed by an extension double-blind treatment period of 16 weeks
To assess the antidepressant efficacy of 3 doses of S 90098 compared to placebo in out-patients suffering from Major Depressive Disorder
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Institut de Recherches Internationales Servier (France)
Update Il y a 4 ans
Efficacy and safety of the S 05985 combination compared with each individual component: randomised, double-blind, placebo-controlled study over eight weeks in hypertensive patients
Not provided at time of registration and not expected to be available in the future
Country
France
,
Hungary
,
Latvia
,
Lithuania
,
Russian Federation
,
Ukraine
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Institut de Recherches Internationales Servier
Update Il y a 4 ans
Comparison of Agomelatine (25 mg/day, adjustement to 50 mg/day) with Escitalopram (10mg/day, adjustement to 20 mg/day) on general interest in outpatients with Major Depressive Disorder over 12 weeks of treatment
To assess the early effect of agomelatine on general interest in outpatient suffering from Major Depressive Disorder
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Institut de Recherches Internationales Servier (France)
Update Il y a 4 ans
Efficacy and safety of agomelatine oral administration (25 to 50 mg/day) in elderly patients suffering from major depressive disorder: an 8-week, randomised, double-blind, flexible-dose, parallel groups, placebo-controlled, international, multicentre study followed by an extension double-blind treatment period of 16 weeks
Not provided at time of registration and not expected to be available in the future
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Institut de Recherches Internationales Servier
Update Il y a 4 ans
Long-term safety study of Abexinostat in patients with haematological malignancies who previously well tolerated Abexinostat
To evaluate long-term safety of S078454 in patients with haematological malignancies who previously well tolerated S078454 and have clinical benefit from long term treatment with S078454
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Institut de Recherches Internationales Servier
Update Il y a 4 ans
Effects of acute and chronic oral administration of S44121 versus placebo on cardiac arrhythmia during exercise testing in patients with catecholaminergic polymorphic ventricular tachycardia type 1
- Evaluation of the effects on the occurence of cardiac arrhythmia during standardized exercise tests (ETs)
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Institut de Recherches Internationales Servier
Update Il y a 4 ans
Exploratory study of S 38093 versus placebo in patients with mild to moderate Alzheimer’s Disease. An international, multi-centre, randomised, double-blind, placebo-controlled phase IIa study
- safety of S 38093 as compared to placebo, - efficacy of S 38093 on cognitive performances, on neuropsychiatric symptoms and symptoms associated with dementia (including apathy and daytime sleepines...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
I.R.I.S. Institut de Recherches Internationales Servier
Update Il y a 4 ans
A one-year multicentre, international, randomised, double-blind study with comparison of benfluorex (150 mg od to 150 mg tid) versus pioglitazone (30 mg od to 45 mg od) in combination with sulfonylurea administered orally for the treatment of type 2 diabetes
Compare the efficacy of benfluorex and pioglitazone in type 2 diabetic patients on top of sulfonylurea over one year of treatment.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Institut de Recherches Internationales Servier
Update Il y a 4 ans
Efficacy and safety of agomelatine (25 mg/day with potential adjustment at 50 mg/day) given orally compared to placebo, in addition to a mood stabilizer in Bipolar I patients with a current major depressive episode. An 8-week randomised, double-blind, controlled, parallel groups study followed by a double-blind extension treatment period up to 1 year
Primary objective: to assess the antidepressant efficacy of agomelatine compared to placebo in addition to a mood stabilizer.
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next